ailab-bio/TACK huggingface dataset:
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2CCC(C3CCN(CC#Cc4ccc(OCCCc5sc(N6CCc7cccc(C(=O)Nc8nc9ccccc9s8)c7C6)nc5C(=O)O)cc4)CC3)CC2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  85 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2CCC3(CC2)CCN(CC#Cc2ccc(OCCCc4sc(N5CCc6cccc(C(=O)Nc7nc8ccccc8s7)c6C5)nc4C(=O)O)cc2)CC3)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  1.5 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2CCC3(CC2)CCN(CC#Cc2ccc(OCCCc4sc(N5CCc6cccc(C(=O)Nc7nc8ccccc8s7)c6C5)nc4C(=O)O)cc2)CC3)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  96 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CC(N3CC(C#Cc4ccc(OCCCc5sc(N6CCc7cccc(C(=O)Nc8nc9ccccc9s8)c7C6)nc5C(=O)O)cc4)C3)C2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  3.9 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CC(N3CC(C#Cc4ccc(OCCCc5sc(N6CCc7cccc(C(=O)Nc8nc9ccccc9s8)c7C6)nc5C(=O)O)cc4)C3)C2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  78 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CC3(CCN(CC#Cc4ccc(OCCCc5sc(N6CCc7cccc(C(=O)Nc8nc9ccccc9s8)c7C6)nc5C(=O)O)cc4)CC3)C2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  1.9 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CC3(CCN(CC#Cc4ccc(OCCCc5sc(N6CCc7cccc(C(=O)Nc8nc9ccccc9s8)c7C6)nc5C(=O)O)cc4)CC3)C2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  97 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CCC3(CC2)CCN(CC#Cc2ccc(OCCCc4sc(N5CCc6cccc(C(=O)Nc7nc8ccccc8s7)c6C5)nc4C(=O)O)c(F)c2)CC3)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  0.8 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CCC3(CC2)CCN(CC#Cc2ccc(OCCCc4sc(N5CCc6cccc(C(=O)Nc7nc8ccccc8s7)c6C5)nc4C(=O)O)cc2)CC3)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  2.6 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CCC3(CC2)CCN(CC#Cc2ccc(OCCCc4sc(N5CCc6cccc(C(=O)Nc7nc8ccccc8s7)c6C5)nc4C(=O)O)cc2)CC3)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  87 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CCC3(CC2)CN(CC#Cc2ccc(OCCCc4sc(N5CCc6cccc(C(=O)Nc7nc8ccccc8s7)c6C5)nc4C(=O)O)cc2)C3)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  4.1 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CC2CCC3(CC2)CN(CC#Cc2ccc(OCCCc4sc(N5CCc6cccc(C(=O)Nc7nc8ccccc8s7)c6C5)nc4C(=O)O)cc2)C3)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  84 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCC(=O)Nc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): CRBN (UniProt Q96SW2)
POI sequence: MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETLTVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRSALLPTIPDTEDEISPDKVILCL
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: HEK293T (Homo sapiens)
Cell line description: Highly susceptible to infection by Zika virus (ZIKV).
CVCL_0045 ! HEK293
In situ; Fetal kidney; 
NCBI_TaxID; 28285; Human adenovirus C serotype 5. NCBI_TaxID; 1891767; Simian virus 40 (SV40) (Note=tsA).
Transformed cell line
Assay time (hours): 24
DC50:  2546.1 nM
Assay description: Degradation of CRBN in HEK293T cells after 24h treatment
Reference: 10.1038/s41598-019-56177-5; https://pubmed.ncbi.nlm.nih.gov/31873151/
Source database: PROTAC-DB; PROTACpedia
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCC(=O)Nc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): CRBN (UniProt Q96SW2)
POI sequence: MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETLTVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRSALLPTIPDTEDEISPDKVILCL
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: HEK293T (Homo sapiens)
Cell line description: Highly susceptible to infection by Zika virus (ZIKV).
CVCL_0045 ! HEK293
In situ; Fetal kidney; 
NCBI_TaxID; 28285; Human adenovirus C serotype 5. NCBI_TaxID; 1891767; Simian virus 40 (SV40) (Note=tsA).
Transformed cell line
Assay time (hours): 24
Dmax:  77.9 %
Assay description: Degradation of CRBN in HEK293T cells after 24h treatment
Reference: 10.1038/s41598-019-56177-5; https://pubmed.ncbi.nlm.nih.gov/31873151/
Source database: PROTAC-DB; PROTACpedia
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCC#Cc2ccc(OCCCc3sc(N4CCc5cccc(C(=O)Nc6nc7ccccc7s6)c5C4)nc3C(=O)O)cc2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  4.6 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCC#Cc2ccc(OCCCc3sc(N4CCc5cccc(C(=O)Nc6nc7ccccc7s6)c5C4)nc3C(=O)O)cc2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  96 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCC#Cc2ccc(OCCCc3sc(N4CCc5cccc(C(=O)Nc6nc7ccccc7s6)c5C4)nc3C(=O)O)cc2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
DC50:  1.8 nM
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCC#Cc2ccc(OCCCc3sc(N4CCc5cccc(C(=O)Nc6nc7ccccc7s6)c5C4)nc3C(=O)O)cc2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): BCL2L1 (UniProt Q07817)
POI sequence: MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEMETPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALREAGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWGRIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLFSRK
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: MOLT-4 (Homo sapiens)
Cell line description: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01 A*01 A*01
Instable (MSI-high).
In situ; Peripheral blood; 
Caucasian.
T-cell; CL=CL_0000084.
Cancer cell line
Assay: Western Blot/CellTiterGlo
Dmax:  91 %
Assay description: BCL-XL Degradation Assay
Cell Culture
Human T lymphoblast MOLT-4 were cultured in RPMI 1640 media, supplemented with 10%FBS. All cell lines were maintained at 37 °C in an atmosphere of 5%CO2.
Protein extraction and Western blotting
Whole cell lysates were prepared using cell Lysis Buffer supplemented with Protease inhibitor, phosphatase inhibitor and PMSF solution. The concentration of protein was quantified using a Pierce Bicinchoninic Acid (BCA) Protein Concentration Kit. Equal amounts of protein were loaded for PAGE and transfer samples onto a PVDF membrane using Bio-Rad's Trans blot. The blots were incubated with a primary antibody followed by HRP conjugated to an appropriate secondary antibody.
Cell viability assay
Cell viability was measured using a CellTiter-Glo Assay kit according to the manufacturer's protocol. MOLT-4 were seeded into 384-well plates and treated with various increasing doses of compound for 72 hours. Cell plates were taken from the incubator and equilibrated withThe plates were read on an Envision 2104 Multi-plate reader using a luminescence detector.
Representative degradation activity and cell viability from exemplary compounds is presented in Table 8.
Reference: BCL-XL DEGRADING COMPOUNDS (patent)
Source database: TPDdb
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCC(=O)Nc2ccc(C(=O)Nc3cc(-c4cccs4)ccc3N)cc2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): HDAC1 (UniProt Q13547)
POI sequence: MAQTQGTRRKVCYYYDGDVGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKANAEEMTKYHSDDYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVASAVKLNKQQTDIAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNYPLRDGIDDESYEAIFKPVMSKVMEMFQPSAVVLQCGSDSLSGDRLGCFNLTIKGHAKCVEFVKSFNLPMLMLGGGGYTIRNVARCWTYETAVALDTEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTNEYLEKIKQRLFENLRMLPHAPGVQMQAIPEDAIPEESGDEDEDDPDKRISICSSDKRIACEEEFSDSEEEGEGGRKNSSNFKKAKRVKTEDEKEKDPEEKKEVTEEEKTKEEKPEAKGVKEEVKLA
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: HCT 116 (Homo sapiens)
Cell line description: African=0%; Native American=0.08%; East Asian, North=1.16%; East Asian, South=0%; South Asian=0.97%; European, North=64.85%; European, South=32.93%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01,02; B*18,45 A*01 A*01 A*01 A*01
Instable (MSI-high).
In situ; Colon; 
Caucasian.
Cancer cell line
Assay time (hours): 24
Dmax:  6 %
Assay description: Degradation of HDAC1 in HCT116 cells after 24 h treatment
Reference: 10.1021/acs.jmedchem.1c02179
Source database: PROTAC-DB
Compound (SMILES): Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCC(=O)Nc2ccc(C(=O)Nc3cc(-c4cccs4)ccc3N)cc2)C(C)(C)C)cc1
Modality: PROteolysis-TArgeting Chimera (PROTAC)
Target protein (POI): HDAC2 (UniProt Q92769)
POI sequence: MAYSQGGGKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKATAEEMTKYHSDEYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVAGAVKLNRQQTDMAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNFPMRDGIDDESYGQIFKPIISKVMEMYQPSAVVLQCGADSLSGDRLGCFNLTVKGHAKCVEVVKTFNLPLLMLGGGGYTIRNVARCWTYETAVALDCEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTPEYMEKIKQRLFENLRMLPHAPGVQMQAIPEDAVHEDSGDEDGEDPDKRISIRASDKRIACDEEFSDSEDEGEGGRRNVADHKKGAKKARIEEDKKETEDKKTDVKEEDKSKDNSGEKTDTKGTKSEQLSNP
E3 ligase: VHL (UniProt P40337)
Ligase sequence: MPRRAENWDEAEVGAEEAGVEEYGPEEDGGEESGAEESGPEESGPEELGAEEEMEAGRPRPVLRSVNSREPSQVIFCNRSPRVVLPVWLNFDGEPQPYPTLPPGTGRRIHSYRGHLWLFRDAGTHDGLLVNQTELFVPSLNVDGQPIFANITLPVYTLKERCLQVVRSLVKPENYRRLDIVRSLYEDLEDHPNVQKDLERLTQERIAHQRMGD
Cell line: HCT 116 (Homo sapiens)
Cell line description: African=0%; Native American=0.08%; East Asian, North=1.16%; East Asian, South=0%; South Asian=0.97%; European, North=64.85%; European, South=32.93%.
Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC Mutation; HGNC; HGNC
A*01,02; B*18,45 A*01 A*01 A*01 A*01
Instable (MSI-high).
In situ; Colon; 
Caucasian.
Cancer cell line
Assay time (hours): 24
Dmax:  6 %
Assay description: Degradation of HDAC2 in HCT116 cells after 24 h treatment
Reference: 10.1021/acs.jmedchem.1c02179
Source database: PROTAC-DB